Compare Boston Scientific Corporation (BSX) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares International Treasury Bond ETF — how do they compare? Boston Scientific Corporation trades at $43.36 (market cap $66.37B), while iShares International Treasury Bond ETF trades at $40.97. The key difference: iShares International Treasury Bond ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | IGOV | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | — |
52-Week High | $108.14 | $43.09 |
52-Week Low | $42.63 | $40.54 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
IGOV trades at $40.58, down 0.64% with a bearish technical signal from moving averages and oscillators. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights downside risks from global inflationary pressures affecting its bond holdings. Support and resistance cluster tightly around $41, indicating a critical price zone.
Outlook remains cautious due to high duration exposure amplifying capital losses in rising rate environments. Investment opportunities are limited by macroeconomic headwinds, while risks include prolonged energy issues and geopolitical tensions impacting performance. Fundamental clarity is needed for a positive reassessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
